Stereotactic body radiotherapy for stage I non-small cell lung cancer

Cleveland Clinic Journal of Medicine

Volumn 79, Issue ELECTRONICSUPPL.1, 2012, Pages 26-31

  Stephans, Kevin ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE FREE SURVIVAL; HUMAN; LUNG FUNCTION TEST; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MORTALITY; PATHOLOGY; RADIATION DOSE; RADIATION RESPONSE; RADIOSURGERY; RECURRENT DISEASE; REVIEW; RISK ASSESSMENT; SURVIVAL RATE; TREATMENT OUTCOME;

CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; LUNG NEOPLASMS; RADIATION TOLERANCE; RADIOSURGERY; RECURRENCE; RESPIRATORY FUNCTION TESTS; RISK ASSESSMENT; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84866761346     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.79.s2.06     Document Type: Article

References (31)

1. Smolle-Juettner FM, Maier A, Lindenmann J, Matzi V, Neuböck N. Resection in stage I/II non-small cell lung cancer. In: Heide J, Schmittel A, Kaiser D, Hinkelbein W, eds. Controversies in the Treatment of Lung Cancer. Basel, Switzerland: Karger; 2010:71-77.
2. McGarry RC, Song G, des Rosiers P, Timmerman R. Observationonly management of early stage, medically inoperable lung cancer:poor outcome. Chest 2002; 121:1155-1158.
3. Lanni TB Jr, Grills IS, Kestin LL, Robertson JM. Stereotactic radiotherapy reduces treatment cost while improving overall survival and local control over standard fractionated radiation therapy for medically inoperable non-small-cell lung cancer. Am J Clin Oncol 2011; 34:494-498.
4. Grutters JP, Kessels AG, Pijls-Johannesma M, De Ruysscher D, Joore MA, Lambin P. Comparison of the effectiveness of radiotherapy with photons, protons and carbon-ions for non-small cell lung cancer: a meta-analysis [published online ahead of print September 3, 2009]. Radiother Oncol 2010; 95:32-40. doi:10.1016/jradonc.2009.08.003
5. Noordijk EM, vd Poest Clement E, Hermans J, Wever AMJ, Leer JWH. Radiotherapy as an alternative to surgery in elderly patients with resectable lung cancer. Radiother Oncol 1988; 13:83-89.
6. Sibley GS. Radiotherapy for patients with medically inoperable stage I nonsmall cell lung carcinoma: smaller volumes and higher doses-a review. Cancer 1998; 82:433-438.
7. Mehta M, Manon R. Are more aggressive therapies able to improve treatment of locally advanced non-small cell lung cancer: combined modality treatment? Semin Oncol 2005; 32(2 suppl 3):S25-S34.
8. Park C, Papiez L, Zhang S, Story M, Timmerman RD. Universal survival curve and single fraction equivalent dose: useful tools in understanding potency of ablative radiotherapy. Int J Radiat Oncol Biol Phys 2008; 70:847-852.
9. Wulf J, Baier K, Mueller G, Flentje MP. Dose-response in stereotactic irradiation of lung tumors. Radiother Oncol 2005; 77:83-87.
10. Timmerman R, Paulus R, Galvin J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 2010; 303:1070-1076.
11. Timmerman R, McGarry R, Yiannoutsos C, et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol 2006; 24:4833-4839.
12. Onishi H, Shirato H, Nagata Y, et al. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer:updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol 2007; 2(7 suppl 3):S94-S100.
13. Nagata Y, Takayama K, Matsuo Y, et al. Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame [published online ahead of print September 19, 2005]. Int J Radiat Oncol Biol Phys 2005; 63:1427-1431. doi: 10.1016/j.ijrobp.2005.05.034
14. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. J Thorac Oncol 2011; 6:2036-2043.
15. Timmerman R, Papiez L, McGarry R, et al. Extracranial stereotactic radioablation: results of a phase I study in medically inoperable stage I non-small cell lung cancer. Chest 2003; 124:1946-1955.
16. Henderson M, McGarry R, Yiannoutsos C, et al. Baseline pulmonary function as a predictor for survival and decline in pulmonary function over time in patients undergoing stereotactic body radiotherapy for the treatment of stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2008; 72:404-409.
17. Stephans KL, Djemil T, Reddy CA, et al. Comprehensive analysis of pulmonary function test (PFT) changes after stereotactic body radiotherapy (SBRT) for stage I lung cancer in medically inoperable patients. J Thorac Oncol 2009; 4:838-844.
18. Yamashita H, Nakagawa K, Nakamura N, et al. Exceptionally high incidence of symptomatic grade 2-5 radiation pneumonitis after stereotactic radiation therapy for lung tumors. Radiat Oncol 2007; 2:21.
19. Dunlap NE, Cai J, Biedermann GB, et al. Chest wall volume receiving > 30 Gy predicts risk of severe pain and/or rib fracture after lung stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys 2010; 76:796-801.
20. Forquer JA, Fakiris AJ, Timmerman RD, et al. Brachial plexopathy from stereotactic body radiotherapy in early-stage NSCLC:dose-limiting toxicity in apical tumor sites. Radiother Oncol 2009; 93:408-413.
21. Stephans KL, Djemil T, Tendulkar RD, Robinson CG, Reddy CA, Videtic GM. Prediction of chest wall toxicity from lung stereotactic body radiotherapy (SBRT) [published online ahead of print February 6, 2011]. Int J Radiat Oncol Biol Phys 2012; 82:974-980. doi:10.1016/j.ijrobp.2010.12.002
22. Hoppe BS, Laser B, Kowalski AV, et al. Acute skin toxicity following stereotactic body radiation therapy for stage I non-smallcell lung cancer: who's at risk? Int J Radiat Oncol Biol Phys 2008; 72:1283-1286.
23. Bradley J. Radiographic response and clinical toxicity following SBRT for stage I lung cancer. J Thorac Oncol 2007; 2(7 suppl 3):S118-S124.
24. Linda A, Trovo M, Bradley JD. Radiation injury of the lung after stereotactic body radiation therapy (SBRT) for lung cancer: a timeline and pattern of CT changes [published online ahead of print December 1, 2009]. Eur J Radiol 2011; 79:147-154. doi:10.1016/j. ejrad.2009.10.029
25. Onishi H, Shirato H, Nagata Y, et al. Stereotactic body radiotherapy (SBRT) for operable stage I non-small-cell lung cancer: can SBRT be comparable to surgery [published online ahead of print July 16, 2011]? Int J Radiat Oncol Biol Phys 2011; 81:1352-1358. doi:10.1016/j.ijrobp.2009.07.1751
26. Lagerwaard FJ, Verstegen NE, Haasbeek CJ, et al. Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I non-small-cell lung cancer [published online ahead of print November 19, 2011.] Int J Radiat Oncol Biol Phys. doi:10.1016/j.ijrobp.2011.06.2003.
27. Neri S, Takahashi Y, Terashi T, et al. Surgical treatment of local recurrence after stereotactic body radiotherapy for primary and metastatic lung cancers. J Thorac Oncol 2010; 5:2003-2007.
28. Crabtree TD, Denlinger CE, Meyers BF, et al. Stereotactic body radiation therapy versus surgical resection for stage I non-small cell lung cancer [published online ahead of print April 18, 2010]. J Thorac Cardiovasc Surg 2010; 140:377-386. doi:10.1016/j. jtcvs.2009.12.054
29. Palma D, Lagerwaard F, Rodrigues G, Haasbeek C, Senan S. Curative treatment of stage I non-small-cell lung acancer in patients with severe COPD: stereotactic radiotherapy outcomes and systematic review [published online ahead of print June 2, 2011]. Int J Radiat Oncol Biol Phys 2012; 82:1149-1156. doi:10.1016/j.ijrobp.2011.03.005
30. Louie AV, Rodrigues G, Hannouf M, et al. Stereotactic body radiotherapy versus surgery for medically operable stage I non-smallcell lung cancer: a Markov model-based decision analysis [published online ahead of print October 6, 2010]. Int J Radiat Oncol Biol Phys 2011; 81:964-973. doi:10.1016/j.ijrobp.2010.06.040
31. Martel MK, Ten Haken RK, Hazuka MB, et al. Estimation of tumor control probability model parameters from 3-D dose distributions of non-small cell lung cancer patients. Lung Cancer 1999; 24:31-37.